This is true in some ways. More patience is definitely required for where we are at. The difference we have with Bisantrene is that it is proven safe (yes RC220 needs to be safe clinically but it’s theoretically the same drug). This drug has been approved. So if/when we get proof of CPACS that will be a game changer and value changer. Very VERY different to other Ph1 drug companies on the market.
RAC Price at posting:
$1.45 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)